-
公开(公告)号：US20190127489A1
公开(公告)日：2019-05-02
申请号：US16124650
申请日：2019-01-21
Applicant: UCB PHARMA S.A.
Inventor： David Paul Humphreys , Emma Dave , Laura Griffin , Sam Philip Heywood
Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US10189897B2
公开(公告)日：2019-01-29
申请号：US14977688
申请日：2015-12-22
Applicant: UCB PHARMA, S.A.
Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
-
公开(公告)号：US10017575B2
公开(公告)日：2018-07-10
申请号：US15242135
申请日：2016-08-19
Applicant: UCB Pharma S.A.
Inventor： Alastair David Griffiths Lawson , Andrew Malcolm Nesbitt , Andrew George Popplewell , Stevan Graham Shaw , Diana Shpektor , Yi Zhang
IPC: C07K16/18 , C07K16/28 , A61K39/395 , A61K45/06 , C07K14/705 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US20180169235A1
公开(公告)日：2018-06-21
申请号：US15887299
申请日：2018-02-02
Applicant: UCB PHARMA, S.A.
Inventor： Martyn K. Robinson
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
-
15.发明申请公开(公告)号：US20180111986A1
公开(公告)日：2018-04-26
申请号：US15534635
申请日：2015-12-11
Applicant: AMGEN INC. , UCB PHARMA S.A.
Inventor： Martyn Kim Robinson , Michael Stuart Ominsky , Xiaodong Li , Hua Zhu Ke
IPC: C07K16/22 , A61P19/08 , A61K39/395 , A61K45/06 , A61P19/10
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P19/08 , A61P19/10 , C07K2317/76 , C07K2317/90 , C07K2317/94
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
-
Patent Agency Ranking
公开(公告)号：US09791462B2
公开(公告)日：2017-10-17
申请号：US14626274
申请日：2015-02-19
Applicant: UCB PHARMA S.A.
Inventor： Mary E. Brunkow , David J. Galas , Brian Kovacevich , John T. Mulligan , Bryan W. Paeper , Jeffrey Van Ness , David G. Winkler
IPC: G01N33/68 , G01N33/84 , C07K14/475 , A61K38/18 , A61K45/06 , G01N33/74 , C07K14/51 , C07K16/18 , C07K16/22 , C12Q1/68 , A61K39/395 , A61K48/00
CPC classification number: G01N33/74 , A01K2217/05 , A01K2217/075 , A61K38/18 , A61K39/3955 , A61K45/06 , A61K48/00 , C07K14/475 , C07K14/51 , C07K16/18 , C07K16/22 , C07K2317/11 , C07K2317/23 , C07K2319/00 , C12N2799/021 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6872 , G01N33/84 , G01N2333/47 , G01N2333/495 , G01N2333/51 , G01N2500/02 , G01N2500/20
Abstract: A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.
-
公开(公告)号：US09657095B2
公开(公告)日：2017-05-23
申请号：US14662538
申请日：2015-03-19
Applicant: UCB PHARMA S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: A61K39/00 , A61K39/395 , C07K16/00 , C07K16/18 , C07K16/22 , C12N1/21 , C12N5/10 , C12N5/12 , C12N15/11 , C12N15/13 , C12N15/63 , C07K14/51 , A61K47/48 , C07K14/475 , G01N33/68
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US09630948B2
公开(公告)日：2017-04-25
申请号：US14909246
申请日：2014-07-28
Applicant: UCB Pharma, S.A.
Inventor： Florian Montel , Eric Jnoff
IPC: A01N43/64 , A61K31/41 , C07D249/08 , C07D403/06
CPC classification number: C07D403/06
Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
-
19.发明授权Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity 有权细菌宿主菌株包含突变体spr基因并具有降低的Tsp活性公开(公告)号：US09587227B2
公开(公告)日：2017-03-07
申请号：US14600089
申请日：2015-01-20
Applicant: UCB PHARMA, S.A.
Inventor： Mark Ellis , David Paul Humphreys
IPC: C12N9/04 , C07K14/245 , C12N9/52 , C12N15/70
CPC classification number: C12N9/0006 , C07K14/245 , C12N9/52 , C12N15/70 , C12Y101/01
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
Abstract translation: 本发明提供了一种重组革兰氏阴性细菌细胞，其包含编码在选自D133，H145，H157，N31，R62,170，Q73，C94，S95，V98中的一个或多个氨基酸具有突变的spr蛋白的突变型spr基因 ，Q99，R100，L108，Y115，V135，L136，G140，R144和G147，并且其中与野生型细胞相比，细胞具有降低的Tsp蛋白活性。
-
公开(公告)号：US09476081B2
公开(公告)日：2016-10-25
申请号：US14451975
申请日：2014-08-05
Applicant: UCB PHARMA S.A.
Inventor： Katharine Lacy Cain , Shirley Jane Peters , Paul Edward Stephens
CPC classification number: C12P21/00 , C07K14/47 , C07K16/00 , C07K16/18 , C07K16/40 , C12N9/0004 , C12P21/02 , Y02P20/52
Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
-
-
-
-
-
-
-
-
-
Search Results
565
records
(took 0.039 seconds)
